FDA delays Orca‑T review as plixorafenib earns breakthrough status and ATOMIC/ASTEROID data reshape colon and lung cancer care ahead of key Q2 decisions.
April 2026 Targeted Pulse
Breast cancer surgery myths, new ALK lung drug filing, safer TIL melanoma prep, ovarian ADC fast track, and statins boosting CAR T outcomes.
FDA oncology updates spotlight SCLC ADC review, NRG1 cholangiocarcinoma filing, new glioma PET imaging, and trial restart.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
2
Myeloma Physicians Consider Approaches to Subcutaneous Therapy
3
Why Clinical Trial Enrollment Matters in the Fight Against Cancer
4
EIK1001 Dose Selected for Registrational Phase 2/3 Melanoma Trial
5